Supported by

Stents and scaffolds

Here you will find all the latest content on stents and scaffolds published on this website. Results are listed in chronological order.

Since 1986, when the first cardiovascular stent was implanted, the development of drug-eluting stents (DES) and the recent introduction of bioresorbable scaffolds have revolutionised interventional cardiology. Keep up-to-date with the latest research; evolving tools, devices and techniques; the role of adjunctive pharmacotherapy; advances in imaging techniques as well as the use of invasive imaging and functional assessment. Find out more…

Filtered By
Stents and scaffolds

533 results

AIDA: BRS: still unanswered questions...

From EUROPCR 2017

Where are we going today with BRS and DES? J. Wykrykowska leads us through two-year results of this all-comer trial comparing ABSORB BRS with metallic DES on a one-to-one ratio. With 1,800 patients, learn why reporting of 2-year data was warranted due to safety concerns. Discover when scaffold thrombosis was seen to increase and whether any relevant predictors for scaffold thrombosis were observed. What still needs to be explored in this emerging technology? Enter the discussion here…

ABSORB Japan: bioresorbable vascular scaffold vs metallic DES in de novo coronary artery lesion

From EUROPCR 2017

What was the nature of the trial designed for BRS approval in Japan? Join K. Kozuma as he underlines the concerns in the use of this “new technology” and discusses current data. Learn why these latest results are positive in terms of safety and efficacy, even in light of the 2-year results which showed higher levels of very late stent thrombosis. Could vessel size play a role? Is a conclusion of non-inferiority with XIENCE near? Understand where we stand today and why by watching now…

Three-year clinical outcomes from ABSORB China

From EUROPCR 2017

As we try to understand emerging BRS devices, we turn to China’s pioneer in interventional cardiology, R-L Gao, who introduces the latest clinical results of ongoing trials pitting BRS against XIENCE. We look at the historical progression of definite or probable stent thrombosis and tease out how these results compare to national and regional trials taking place throughout the world. Looking at the increasingly positive results, we explore the role that patient selection or vessel size play.

SCAAR - Outcome of PCI with the Abbott everolimus-eluting BRS vs. modern DES

From EUROPCR 2017

From one of the foremost historic registries in our field, P. Grimfjärd looks at the performance of ABSORB BRS and compares it with other, currently used DES in this all-comers study. What were the overall outcomes in the Swedish cohort when you look at all BRS implanted between 2011 and 2016? What did the investigators find in terms of stent thrombosis or restenosis? Learn more here...

DESolve Novolimus Eluting Coronary BRS

From EUROPCR 2017

Five year results of a fully bioresorbable novolimus-eluting coronary scaffold system: what began as a question of looking into the short-term safety and efficacy of an innovative BRS is now playing out in the long-term with equally surprising results. For the first time, a BRS has been shown to degrade within 6-9 months with absorption within one year. With S. Verheye we learn about the implications of this device and explore the current data including TLR, mortality and scaffold thrombosis. Watch here…

A look at second-generation bioresorbable scaffolds: BIOSOLVE II and BIOSOLVE III

From EUROPCR 2017

Bioresorbable scaffolds continued to take centre stage at EuroPCR 2017. M. Haude introduces us to two trials with results from a newer-generation device with a unique magnesium alloy backbone. How does this backbone differ from PLLA? Is the absorption time different? What were the results in terms of safety, and the all-important consideration of stent thrombosis? Does this device handle differently from other bioresorbable devices, such as in trackability? And what about these 2-year results, now out of the timeframe of DAPT use? Learn what has been achieved – and what still needs to be done – here…

EuroPCR 2017: ABSORB China 3 year clinical outcomes

Supported by ABBOTT VASCULAR

EuroPCR 2017: ILUMIEN III substudy: what is the reach of the novel OCT-based stent implantation algorithm?

The ILUMIEN III randomized study showed non-inferiority of OCT-guided stent implantation to achieve optimal stent expansion compared with IVUS guidance.

EuroPCR 2017 Highlights: Coronary Interventions

20 May 2017

From the standpoint of 40 years of angioplasty, 20 years of physiological assessment and emerging data on a variety of topics, J. Byrne and T. Johnson review data published at EuroPCR 2017. Interest remains intense concerning bioresorbable stents (BRS) with ongoing international trials and whether evolving new devices and techniques will answer the problem of thrombosis. Complex interventions such as CTO showed interesting data and the evolution in our use of iFR or FFR continues to demonstrate the role innovation plays in our specialty, hereby better understanding physiology to improve treatment strategies and positively impacting outcome.

How should I treat edge restenosis lesion after implantation of an everolimus-eluting metallic stent?

19 May 2017

A 60-year-old male presented with newly developed exertional chest pain. He had undergone percutaneous coronary intervention with a drug-eluting stent (DES) in the mid left anterior descending (LAD) artery at another hospital two years ago...